Overview
Steadiwear offers the Steadi-3 Plus, a hand tremor device designed for patients with Essential Tremor and Parkinson's Disease. The company provides resources for both patients and providers, including a validation study and comparison information.
Key people
In the news
- Our CMO/COO, Emile Maamary, recently sat down with Rogers tv Built: In Waterloo for a conversation on navigating startup growth with first-to-market tech. Thank you to Danielle Joworski and the Rogers team for having him. Watch the full segment: https://lnkd.in/g2YrHJZu
- Young-onset Parkinson's disease (onset ~21–40) is clinically its own subtype, and the framing matters for anyone supporting a younger patient or colleague. What distinguishes it: • Slower motor progression than late-onset disease — many people work and parent for years after diagnosis • Earlier levodopa-related motor complications (dyskinesia, fluctuations), which makes medication sequencing a genuinely long-horizon, specialist-led decision • A higher genetic contribution (variants such as PARKIN, PINK1, DJ1), relevant to
- Eating difficulty in Parkinson's is often read as "just the tremor," but it rarely is — it draws on tremor, bradykinesia, rigidity, and reduced grip at once. That framing changes what actually helps. Practical, evidence-aware strategies clinicians and caregivers can apply: • Proximal stabilization — bracing the forearm converts a whole-arm tremor into a smaller wrist movement; reducing the precision each mouthful demands beats trying to force steadiness • Manage the weighted-utensil myth — a randomized controlled trial found
- One of the most common questions a shaking hand raises is: is this Parkinson's, or essential tremor? The distinction is worth understanding, because it hinges on a single, observable feature — timing. A Parkinson's tremor is a resting tremor: it appears when the hand is still and supported, is typically slow (about 4–6 Hz) with a "pill-rolling" quality, usually begins on one side, and characteristically eases when the hand is put to use. Essential tremor is the mirror image — an action tremor that emerges during
- We are very happy to share our latest feature in the press. “We see individuals who are able to get back to drinking a glass of water, eating comfortably, and really having their confidence in their own movements restored,” says Mark Elias , CEO of Steadiwear. “When we hear those kinds of reviews, that they’re able to get back to their hobbies, to draw again, it makes everything worthwhile.” Big thank you to Andrea Yu at the The Globe and Mail for the stellar coverage. A link to the full story is in the comments
- Is the DBS still working?" is one of the harder questions in a long-term movement-disorders clinic, and the honest answer requires holding two facts at once. First: thalamic Vim-DBS is genuinely durable. Long-term series report roughly 70–80% improvement in tremor and handwriting maintained over years, and large single-center experience confirms sustained control at long follow-up. Second: that benefit is not fixed, and the data say so plainly: • The same series that show sustained benefit also show stimulation parameters escalating
- We'll start first-line therapy" is one of the most common sentences in an essential tremor consult and the expectation set in that moment often outruns what the evidence supports. A quick evidence check on propranolol and primidone, the two Level A agents: • The Level A grade rests on small, largely decades-old double-blind trials (often 10–20 patients). The effect is real and replicated, but the precision and long-horizon data a modern dossier would carry simply aren't there. • Benefit is meaningful but partial — short-term
- Is it time to consider surgery?" is a question patients with essential tremor often sit on far too long, either assuming their tremor isn't "bad enough," or fearing that a procedure is a drastic last resort. A clearer framework helps. The threshold rests on two signposts worth reinforcing with patients: • Medication genuinely exhausted — first-line agents (propranolol, primidone) trialled at adequate doses, often with a second-line add-on, without sufficient control. Inadequate response affects an estimated 25–55%, so this is
Something wrong or missing? Send an update. Fixed within 24 hours.